Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.

Autor:	Giovannoni G; Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK., Comi G; Casa di Cura Privata del Policlinico, Universita Vita-Salute San Raffaele, Milan, Italy., Rammohan K; MS Research Center, University of Miami School of Medicine, Miami, FL, USA., Rieckmann P; Department of Neurology, Medical Park Loipl & University of Erlangen, Erlangen, Germany., Dangond F; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA., Jack D; Merck Serono Ltd., Feltham, UK, an affiliate of Merck KGaA., Vermersch P; Univ. Lille, INSERM U1172, Lille Neurosciences & Cognition, CHU Lille, FHU Precise, Lille, France.
Jazyk:	angličtina
Zdroj:	Neurodegenerative disease management [Neurodegener Dis Manag] 2022 Dec; Vol. 12 (6), pp. 295-301. Date of Electronic Publication: 2022 Aug 26.
DOI:	10.2217/nmt-2022-0018
Abstrakt:	What Is This Summary About?: This is a summary of an article originally published in the journal Advances in Therapy . Cladribine tablets are approved for treating people with relapsing multiple sclerosis (shortened to MS). People with MS take cladribine tablets for 2 periods of 4 to 5 days per year. This analysis looks at the results from 2 studies called the CLARITY and CLARITY Extension studies. These studies looked at what effect a 2-year course of treatment with cladribine tablets had on disability over 5 years in people with MS. How Was the Analysis Carried Out?: In this analysis, researchers measured disability worsening at regular intervals during the 2-year treatment period in the CLARITY study and thereafter in the 2-year CLARITY Extension study. As many patients had a bridging interval between CLARITY and CLARITY extension, the researchers were able to assess disability over a 5-year timeframe. What Were the Results?: When measurements were taken at Year 5 of the study, disability remained stable in more than half of participants. Over the 5-year period, 70% of participants did not experience persistent disease worsening that lasted more than 6 months. What Do the Results Mean?: Researchers concluded that a 2-year course of cladribine tablets may provide long-term benefits on disability for up to 5 years. Clinical Trial Registration : NCT00213135 (ClinicalTrials.gov) Clinical Trial Registration : NCT00641537 (ClinicalTrials.gov).
Databáze:	MEDLINE
Externí odkaz: